Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: Clinical outcomes, quality of life, and costs

Blood

Volumn 100, Issue 8, 2002, Pages 2697-2702

  Lee, Stephanie J ^a,b   Zahrieh, David ^a,b   Alyea, Edwin P ^a,b   Weller, Edie ^a,b   Ho, Vincent T ^a,b   Antin, Joseph H ^a,b   Soiffer, Robert J ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CD45 ANTIGEN; CD6 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS;

ACUTE LEUKEMIA; ADULT; AGE; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE ASSOCIATION; DONOR; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEALTH CARE COST; HEALTH SURVEY; HLA MATCHING; HOSPITALIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; SCORING SYSTEM; T LYMPHOCYTE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 0037108291     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-03-0984     Document Type: Article

References (21)

1. National Marrow Donor Program. History of stem cell transplants. Available at http://www.marrow.org/NMDP/history_stem_cell_transplants.html. Accessed December 1, 2001.
2. Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med. 1993;328:593-602.
3. McGlave P, Bartsch G, Anasetti C, et al. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. Blood. 1993;81:543-550.
4. Drobyski WR, Ash RC, Casper JT, et al. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood. 1994; 83:1980-1987.
5. Devergie A, Apperley JF, Labopin M, et al. European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia: impact of HLA class II matching. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1997;20:11-19.
6. Soiffer RJ, Weller E, Alyea EP, et al. CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. J Clin Oncol. 2001;19:1152-1159.
7. Ho VT, Weller E, Lee SJ, Alyea EP, Antin JH, Soiffer RJ. Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001;7:223-229.
8. Moscardo F, Sanz GF, de La Rubia J, et al. Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34(+) positive selection. Bone Marrow Transplant. 2001;27:983-988.
9. Soiffer RJ, Murray C, Mauch P, et al. Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. J Clin Oncol. 1992; 10:1191-1200.
10. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825-828.
11. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204-217.
12. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey: A Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Center; 1993.
13. Hjermstad MJ, Loge JH, Evensen SA, Kvaloy SO, Fayers PM, Kaasa S. The course of anxiety and depression during the first year after allogeneic or autologous stem cell transplantation. Bone Marrow Transplant. 1999;24:1219-1228.
14. Spitzer WO, Dobson AJ, Hall J, et al. Measuring the quality of life of cancer patients: a concise OL-index for use by physicians. J Chronic Dis. 1981;34:585-597.
15. Bureau of Labor Statistics. Consumer Price Index. Available at http://www.bls.gov. Accessed June 1, 2001.
16. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
17. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Annals of Statistics. 1998;16:1141-1154.
18. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS System for Mixed Models. Cary, NC: SAS Institute; 1996.
19. The SAS Institute. SAS Release 8.1. Cary, NC: SAS Institute; 2002.
20. Sehn LH, Alyea EP, Weller E, et al. Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion. J Clin Oncol. 1999;17:561-568.
21. Champlin RE, Passweg JR, Zhang MJ, et al. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood. 2000;95:3996-4003.